Clinical trial · Observational
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands
NCT01215526CI-TRIAL-00018892FAST-NLcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To estimate the progression-free survival (PFS) failure rate
- timeFrame
- Maximum 3 years
Secondary outcomes (4)
- measure
- To enhance the knowledge on known undesirable effects under routine conditions and to obtain further knowledge about so far unknown and rare undesired effects
- timeFrame
- Every 3 months (during 3 years)
- measure
- To prescribe the change in patient's quality of life (QoL) during therapy.
- timeFrame
- From study start and after 6 months
- measure
- To assess the improvement of IPSS from baseline after 3 months of Firmagon therapy and at end-of-therapy
- timeFrame
- From study start, after 3 months and at end of treatment
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: \- Patients with advanced hormone-dependent prostate carcinoma that are eligible for hormone therapy Exclusion Criteria: \- Patients with a contraindication for prescription of Firmagon®
References
Publications (0)
Data not yet available
No reference posted for this study.